WaveMan
WaveMan · Company
GNPX · Genprex, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GNPX Genprex (GNPX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001595248
Quote by TradingView
Congress · 1
Insider buyers, 180 days
0
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about GNPX

Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-02-05

Genprex insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Genprex, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
LONGNECKER BRENT M
Director
SELL
2026-04-15 SECtraded 2026-04-14
8
$10
-93.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 0.1% of the 9,157 shares held after it.
  • No other insider sold within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LONGNECKER BRENT M sold about $10 of GNPX on Apr 14, 2026, the largest insider sale at the company on our record; 10 funds added in the latest 13F quarter.
LONGNECKER BRENT M
Director
SELL
2026-04-15 SECtraded 2026-04-14
10
$12
-93.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • No other insider sold within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director LONGNECKER BRENT M sold about $12 of GNPX on Apr 14, 2026, the largest insider sale at the company on our record; 10 funds added in the latest 13F quarter.
Varner John Rodney
Chairman, President and CEO
BUY
2023-04-24 SECtraded 2023-04-21
19,000
$20.1K
-100.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 91.3% of the 20,800 shares held after it.
  • 1 other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President and CEO Varner John Rodney bought about $20.1K of GNPX on Apr 21, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 10 funds added in the latest 13F quarter.
VACZY CATHERINE M
EVP GC Chief Strategy Officer
BUY
2023-04-24 SECtraded 2023-04-21
20,000
$21.4K
-100.0%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 7.5% of the 265,000 shares held after it.
  • 1 other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP GC Chief Strategy Officer VACZY CATHERINE M bought about $21.4K of GNPX on Apr 21, 2023, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 10 funds added in the latest 13F quarter.
4 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.9% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch GNPX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-99.1%12M
-99%-64%-30%+5%2025-102025-122026-022026-042026-062026-08 2026-04-14 · LONGNECKER BRENT M sold $122026-04-14 · LONGNECKER BRENT M sold $10
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GNPX: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD FIDUCIARY TRUST CO
78,104 sh
$40.5K
GEODE CAPITAL MANAGEMENT, LLC
60,348 sh
$31.3K
VANGUARD CAPITAL MANAGEMENT LLC
36,350 sh
$18.9K
Engineers Gate Manager LP
20,885 sh
$10.8K
Mayflower Financial Advisors, LLC
20,000 sh
$10.4K

Congress trades in GNPX

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Tim Moore
Bought 2026-02-05 · disclosed 15 days later
$1,001 - $15,000
Tim Moore
Bought 2025-12-18 · disclosed 20 days later
$1,001 - $15,000
Tim Moore
Bought 2025-11-07 · disclosed 25 days later
$1,001 - $15,000
Tim Moore
Bought 2025-10-29 · disclosed 14 days later
$15,001 - $50,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GNPX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GNPX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$19.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$3.1K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$1.2K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$534 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
2
Multi-phase
2 active
What changed recently
Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patie
2026-09-12 · Completion moved 2026-06 → 2027-12
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Ryan MConfer
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$728.9K
$906.3K
$688.6K
n/a
n/a
2023
$1.7M
$909.6K
$940.2K
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. This filer reported no return figures.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 10 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GNPX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2022-01-01 to 2022-12-31
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$15.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-203.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-157.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-195.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
n/a
no debt line filed
FCF yield
-1,049%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenuen/a$0$0$0
Operating income-$15.5M-$21.2M-$31.1M-$23.8M
Net income-$16.2M-$21.4M-$30.9M-$23.7M
Operating cash flow-$15.3M-$17.9M-$24.7M-$17.6M
Cash$7.8M$1.6M$6.7M$21.0M
SEC XBRL, fiscal years, as known on 2026-10-28

GNPX Stock Sonar score 3/7 axes

Find similar shapesCompare

GNPX ranks highest on risk and compliance (55th percentile) and institutional and government (39th), and lowest on profitability (14th), among Pharma & Biotech peers.

Profitability
14
Inputs
  • Return on equity-203.9% · 16 pct, sector of 545
  • Return on assets-157.4% · 15 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-195.8% · 10 pct, sector of 576
Institutional and government
39
Inputs
  • Funds adding, latest quarter10 · 18 pct, sector of 698
  • Congress net buyers, 365d1 · 60 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
  • Short interest, % of float+11.9% · 34 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.3% · 76 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GNPX filings, in plain words

Have members of Congress traded GNPX?

Yes. In the year to 2026-10-28, 1 House member disclosed buying GNPX and 0 House members disclosed selling it; the latest on record is a purchase by Tim Moore dated 2026-02-05.

Read the full summary

In the year to 2026-10-28, 1 member of Congress disclosed buying GNPX and 0 members disclosed selling it; the latest on record is a purchase by Tim Moore dated 2026-02-05. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies